Basel, Switzerland
Arvelle Therapeutics, founded in 2019 and headquartered in Switzerland, operates in the Biotechnology industry with a focus on Central Nervous System (CNS) disorders. The company aims to deliver groundbreaking solutions for patients with these challenges, living up to its slogan: "A biopharmaceutical company committed to delivering groundbreaking solutions for patients with CNS disorders."
Arvelle Therapeutics excels in developing cutting-edge treatments, positioning itself as a significant player in the CNS therapeutic landscape. Their last investment, a $42.70M Series A round on 27 May 2020, featured support from a consortium of seasoned investors, including F-Prime Capital, H.I.G. BioHealth Partners, KB Investments, Andera Partner, Novaquest Capital Management, BPV Capital Management - Back Porch Vista, and EQT Life Sciences. This financial backing underscores confidence in Arvelle's strategic vision and market potential.
